H. Patel

发表

A quantitative analysis of kinase inhibitor selectivity

Mindy I. Davis, L. Wodicka, P. Zarrinkar, 2008, Nature Biotechnology.

A small molecule–kinase interaction map for clinical kinase inhibitors

L. Wodicka, D. Lockhart, P. Zarrinkar, 2005, Nature Biotechnology.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

P. Zarrinkar, Mazen W. Karaman, G. Pallares, 2009, Blood.

A preliminary examination of the structure of gels and emulsions containing cetostearyl alcohol and cetrimide using Laser Raman Spectroscopy

H. Patel, R. Rowe, J. Louden, 1985 .

Properties of cetrimide/cetostearyl alcohol ternary gels; preparation effects

H. Patel, R. Rowe, R. Stewart, 1985 .

A systematic microscopical examination of gels and emulsions containing cetrimide and cetostearyl alcohol

H. Patel, R. Rowe, R. Stewart, 1985 .

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

Mixed micelles of alkyltrimethylammonium bromides and chlorhexidine digluconate in aqueous solution

H. Patel, D. Attwood, 1989 .

Self micro-emulsifying drug delivery system of tacrolimus: Formulation, in vitro evaluation and stability studies

H. Patel, T. Mehta, S. Panchal, 2013, International journal of pharmaceutical investigation.

Formulation strategies for drug delivery of tacrolimus: An overview

H. Patel, T. Mehta, S. Panchal, 2012, International journal of pharmaceutical investigation.

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Daniel K. Treiber, John Kuriyan, David J. Lockhart, 2006, Cancer research.

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

William Pao, Harold Varmus, Daniel K Treiber, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Development and characterization of liquid and solid self-microemulsifying drug delivery system of Tacrolimus

H. Patel, M. Patel, Pranav Patel, 2012 .

Formulation Development and Characterization of Darunavir and Ritonavir Immediate Release Tablets using Quality by Design approach

H. Patel, J. Patel, P. Dhaval, 2021 .

treatment of acute myeloid leukemia (AML) AC220 is a uniquely potent and selective inhibitor of FLT3 for the

P. Zarrinkar, Mazen W. Karaman, G. Pallares, 2013 .

Mixed micelles of tetradecyltrimethylammonium bromide and chlorhexidine digluconate in aqueous solutions of isopropyl alcohol

H. Patel, V. Mosquera, D. Attwood, 1988 .

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

P. Zarrinkar, Mazen W. Karaman, H. Patel, 2009, Blood.

Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.

D. Lockhart, P. Zarrinkar, D. K. Treiber, 2009, Bioorganic & medicinal chemistry letters.